The 2019 Scientific Report of the Sant Pau Biomedical Research Institute (IIB Sant Pau) is now available. You can consult it on its website.
Scientific Report of the Sant Pau Biomedical Research Institute (IIB Sant Pau)
The 2019 Scientific Report of the Sant Pau Biomedical Research Institute (IIB Sant Pau) is now available. You can consult it on its website.
Dr. Kulisevsky, director of the Movement Disorders Unit of the Sant Pau Hospital Neurology Service and head of the Parkinson’s Disease and Movement Disorders Research Group at the Sant Pau Research Institute, is the principal investigator and international coordinator of a controlled phase 2 drug study that, for the first time in 20 years, is achieving positive results for cognitive complications in Parkinson’s disease. Sant Pau Hospital has also participated as a patient recruitment centre for the study.
Luciana Martel, PhD student and member of the Pituitary Diseases Research Group at the Sant Pau Research Institute -IIB Sant Pau, led by Susan Webb, has received the award for best paper from the Neuroendocrinology Area for her work “Gender Dimorphism in Skeletal Muscle Fat Infiltration and Associated Muscle Dysfunction in Patients with Controlled Acromegaly” at the congress of the Spanish Society of Endocrinology and Nutrition (SEEN), which was recently held in virtual format.
On 28 October, the “Orphan Drug Designation, Development and Access” conference will take place online for the first time. Among other speakers, Dr. Jordi Minguillón, a researcher with the Sant Pau Research Institute’s Genomic Instability Syndromes and DNA Repair research group, and Dr. Josep Torrent-Farnell, pharmacologist and coordinator of rare diseases and orphan drugs at the Sant Pau Hospital’s Clinical Pharmacology Service, will participate in the conference. Attached you will find the programme and the registration forms.
Today, 19 October, World Breast Cancer Day, the Hospital de Sant Pau also commemorates the fact that the female team formed by Dr. M. Carmen Alonso and Dr. Montserrat Baiget, both from the Hospital de Sant Pau, were pioneers in the study of hereditary breast and ovarian cancer by searching for the mutations in the BRCA 1 and 2 genes that predispose to these two types of disease. The Hospital de Sant Pau currently has one of the largest genetic databases in the world with over 2,000 samples.
On the occasion of World Thrombosis Day, the Sant Pau Modernist Site is hosting a commemorative event on Friday 20 November from 5 p.m. to present the ACTIVA’TT Association and its activities in the field of research and prevention. The Mobile Centre for the Evaluation of Vascular Diseases, the Association’s main tool for raising funds to finance research projects at the Sant Pau Research Institute, will also be presented.
The Cerebral Vascular Disease research group, led by Dr. Joan Martí Fàbregas, inaugurates the Sessions of experts in #patologiavascularcerebral of the @scatalananeuro (Catalan Neurology Society) at the IIB Sant Pau in online format. If you want to connect, the appointment is tomorrow Friday, 10/09 at 8:30 am through the following link: https://lnkd.in/ekATWex
An investigation by the Research Groups of the Neuromuscular Diseases Unit (Alonso-Pérez and Díaz-Manera) and of Genetic Diseases (Gallano and González-Quereda), of the Sant Pau Research Institute- IIB Sant Pau, has recently been published in the Brain journal. The results of the study, in which 33 hospitals from 13 European countries participated and which collected clinical and genetic data from 439 muscular dystrophy patients, will help to design new clinical trials in a more rational way, while indicating that those therapies that induce protein expression above 30% can produce a significant change in the natural history of the disease.
The Cardiovascular Risk Metabolic Basis Research Group of the Sant Pau-IIB Sant Pau Research Institute, attached to CIBERDEM, is collaborating on research which identifies a new mechanism involved in the development of atherosclerotic lesions.
Dr. Jose Maria Guerra, an assistant doctor in the Cardiology Service at the Hospital de Sant Pau and coordinator of the Clinical and Translational Cardiology Research Group at the Sant Pau Research Institute, attached to the CIBERCV, has recently been appointed a member of the Scientific Initiatives Committee of the European Heart Rhythm Association-European Society of Cardiology (EHRA-ESC).
Researchers from Sant Pau have published an article in Frontiers in Medicine (journal of the first quartile of the Internal Medicine area) where they analyse the incidence and predictive factors of pulmonary embolisms or thrombosis in patients hospitalised with Covid-19. The research has concluded that the incidence of 2.6% of pulmonary embolisms or thrombosis in patients hospitalized with Covid-19 is clearly high.
Researchers from the Clinical Epidemiology and Health Services Research Group of the Sant Pau Research Institute -IIB, led by Laura Martínez, together with the updating working group of the Guideline International Network and other collaborators, have developed an “UpPriority” tool that provides a simple prioritisation strategy to determine which clinical questions included in a CPG need to be preferentially updated, as detailed by the authors in a recent article published in the Journal of Clinical Epidemiology.
La Dra. Lorena Alba Castellón, del Grupo de Investigación de Oncogénesis y Antitumorales del Instituto de Investigación del Hospital de Sant Pau – IIB Sant Pau, ha obtenido una ayuda postdoctoral de la Asociación Española Contra el Cáncer (AECC) para su proyecto Cancer Associated Firbroblast-Tarageted Nanoparticles to Improve Antimetastastic Therapyn Colorectal Cancer. Esta ayuda ha sido entregada por la AECC con motivo del Día Mundial de la Investigación en Cáncer (World Cancer Research Day) que se celebra el 24 de septiembre.
New research has shown that virgin olive oil enriched with its own phenolic compounds increases the ability of HDL particles (high-density lipoproteins) to transport cholesterol deposited on the arterial wall for subsequent elimination from the body, through the liver and intestine. The work, published in the journal Biomedicines, has been coordinated by researchers from CIBER in the areas of Diabetes and Associated Metabolic Diseases (CIBERDEM) and Physiopathology of Obesity and Nutrition (CIBEROBN), the Research Institute and Hospital de la Santa Creu i Sant Pau, the Hospital del Mar Institute for Medical Research (IMIM), Rovira i Virgili University, the University of Lleida and the Institute of Vine and Wine Sciences-ICVV.
Reference article: https://www.mdpi.com/2227-9059/8/8/266
The Research Institute of the Hospital de Sant Pau – IIB Sant Pau participates in a study published in the journal Science that reveals that biological sex has a small but widespread influence on the gene expression of almost every type of human tissue. Genes that are estimated to be expressed at different levels in adult women and men are involved in many different biological processes, including response to medication, control of blood glucose levels during pregnancy, and cancer.
Reference article: https://doi.org/10.1126/science.aba3066
M. Rosa Ballester Verneda, researcher at the Drug Research Center (CIM), has recently been elected Research and Teaching Member of the Governing Board of the Barcelona College of Pharmacists.
A study led by Dr. Pere Domingo, coordinator of the HIV and AIDS Research Group and hospitalization COVID of the Sant Pau Research Institute -IIB Sant Pau and member of the Infectious Diseases Unit of the Hospital de Sant Pau analyzes the pathogenesis of COVID -19 as the dynamic interaction between four circles that occur simultaneously. One more step to understand the mechanism that the virus uses to bypass the host’s immune defense mechanisms, or the mechanisms it uses to harm, and that will allow designing appropriate strategies to neutralize the dysfunctions or imbalances generated by the virus or by the consequences of the infection.
Thanks to the work coordinated by Dra. Maria Pía Gallano, director of the Genetic Diseases Research Group at the Sant Pau Research Institute, in which researchers from various centers also affiliated to CIBERER have participated, has designed a genetic panel of mass sequencing (NGS) with great power diagnosis for people affected by neuromuscular diseases such as myopathies, muscular dystrophies, and previously undiagnosed congenital myasthenic syndromes.
See more
With this NGS panel, they analyzed a cohort of 207 patients in Spain and detected the cause of the disease in 102, 49% of them, in 42 genes. Thus, this panel is constituted as a tool for the analysis of genes related to neuromuscular diseases that offers reliable results in a short period of time and relegates invasive techniques to later stages. The work has been published in the journal Genes.
More information
The Fundació Institut de Recerca del Hospital de la Santa Creu i Sant Pau has recently become a member of the Bioinformatics Barcelona Association (BIB), a non-profit association for education and training, promoting advanced research , knowledge and technology transfer, stimulating competitiveness and innovation within the industrial sector, and providing greater international visibility in the field of bioinformatics.
The Foundation of the Research Institute of the Hospital de la Santa Creu i Sant Pau joins the Aliança Instituts de Recerca i Innovació en salut de Catalunya (IRISCAT). The main objectives of this agreement are the creation of a cooperative workspace that operates under the name IRISCAT to better take advantage of the advantages conferred by the dimension and high level of standards of the healthcare and research organization in which they operate, with the vision of improving the translational and clinical research of the Catalan Health System; also the preparation of a strategic Plan for its development that considers the needs and implications necessary for its implementation and the achievement of the objective of exploitation and integration of economies of scale in the different fields of action and the creation of a Technical Office, with the objective to coordinate the implementation of the execution process of the actions contemplated in the Strategic Plan of the IRISCAT Alliance.